PE20200614A1 - Molecula de polipeptido con especificidad dual mejorada - Google Patents

Molecula de polipeptido con especificidad dual mejorada

Info

Publication number
PE20200614A1
PE20200614A1 PE2020000056A PE2020000056A PE20200614A1 PE 20200614 A1 PE20200614 A1 PE 20200614A1 PE 2020000056 A PE2020000056 A PE 2020000056A PE 2020000056 A PE2020000056 A PE 2020000056A PE 20200614 A1 PE20200614 A1 PE 20200614A1
Authority
PE
Peru
Prior art keywords
polypeptide molecule
dual specificity
enhanced dual
region derived
binding region
Prior art date
Application number
PE2020000056A
Other languages
English (en)
Inventor
Felix Unverdorben
Dominik Maurer
Sebastian Bunk
Martin Hofmann
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/de
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PE20200614A1 publication Critical patent/PE20200614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una molecula de polipeptido biespecifica que comprende una primera cadena polipeptidica y una segunda cadena polipeptidica que proporciona una region de union derivada de un receptor de linfocito T (TCR) que es especifica para un epitopo peptidico virico asociado al complejo principal de histocompatibilidad (MHC), y una region de union derivada de un anticuerpo capaz de reclutar celulas efectoras inmunitarias humanas mediante la union especifica a un antigeno de superficie de dichas celulas, asi como metodos para fabricar la molecula de polipeptido biespecifica, y usos de la misma
PE2020000056A 2017-07-14 2018-07-13 Molecula de polipeptido con especificidad dual mejorada PE20200614A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
DE102017115966.5A DE102017115966A1 (de) 2017-07-14 2017-07-14 Polypeptidmolekül mit verbesserter zweifacher Spezifität
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
DE102018108995 2018-04-16
PCT/EP2018/069157 WO2019012141A1 (en) 2017-07-14 2018-07-13 IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY

Publications (1)

Publication Number Publication Date
PE20200614A1 true PE20200614A1 (es) 2020-03-11

Family

ID=62951983

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000058A PE20200615A1 (es) 2017-07-14 2018-07-13 Molecula de polipeptido con especificidad dual mejorada
PE2020000056A PE20200614A1 (es) 2017-07-14 2018-07-13 Molecula de polipeptido con especificidad dual mejorada

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020000058A PE20200615A1 (es) 2017-07-14 2018-07-13 Molecula de polipeptido con especificidad dual mejorada

Country Status (28)

Country Link
US (7) US11905328B2 (es)
EP (3) EP3652215B1 (es)
JP (4) JP2020530762A (es)
KR (2) KR20200026994A (es)
CN (2) CN110914308A (es)
AU (2) AU2018298884A1 (es)
BR (2) BR112020000769A2 (es)
CA (2) CA3069842A1 (es)
CO (2) CO2020001029A2 (es)
CR (2) CR20200013A (es)
CY (2) CY1124091T1 (es)
DK (2) DK3428194T3 (es)
ES (2) ES2871146T3 (es)
HR (1) HRP20211744T1 (es)
HU (2) HUE054568T2 (es)
LT (2) LT3652215T (es)
MA (1) MA46299B1 (es)
MD (2) MD3652215T2 (es)
MX (1) MX2020011744A (es)
PE (2) PE20200615A1 (es)
PL (2) PL3652215T3 (es)
PT (2) PT3428194T (es)
RS (2) RS62544B1 (es)
SG (2) SG11202000025SA (es)
SI (2) SI3428194T1 (es)
TW (2) TWI762677B (es)
WO (2) WO2019012138A1 (es)
ZA (1) ZA202000842B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018298884A1 (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
EP3794035A1 (en) 2018-05-14 2021-03-24 Immunocore Limited Bifunctional binding polypeptides
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
EP3976805A1 (en) 2019-05-27 2022-04-06 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
JP2023504530A (ja) * 2019-12-05 2023-02-03 アーベル リミテッド ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
JP2024518378A (ja) 2021-05-05 2024-05-01 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230190807A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
CA3240046A1 (en) * 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023209124A1 (en) 2022-04-29 2023-11-02 Immatics Biotechnologies Gmbh Mammalian display platform for multispecific antigen binding proteins
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024033332A1 (en) 2022-08-08 2024-02-15 Immatics Biotechnologies Gmbh Guided positional scanning method
WO2024130179A1 (en) 2022-12-16 2024-06-20 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2024146936A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules against a piwil1 peptide-hla complex
US20240228617A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1294904A1 (en) 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
EP1438400B1 (en) 2001-10-01 2009-06-17 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
JP2008535826A (ja) 2005-04-01 2008-09-04 メディジーン リミテッド 高親和性ｈｉｖｔ細胞レセプター
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
WO2009087230A1 (en) 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
LT2519543T (lt) 2009-12-29 2016-10-10 Emergent Product Development Seattle, Llc Heterodimerus rišantys baltymai ir jų panaudojimas
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP2647707B1 (en) 2010-11-30 2018-09-12 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
SG10201602159VA (en) 2011-02-11 2016-04-28 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
US20130078250A1 (en) * 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
RU2015125639A (ru) 2012-11-30 2017-01-10 Роше Гликарт Аг Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i
KR20210094673A (ko) * 2013-02-26 2021-07-29 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
KR20150122203A (ko) 2013-02-26 2015-10-30 로슈 글리카트 아게 T 세포 활성화 이중특이적 항원 결합 분자
CN111925437A (zh) * 2013-03-14 2020-11-13 宏观基因有限公司 与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
JP6817064B2 (ja) 2013-11-27 2021-01-20 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
LT3736292T (lt) 2013-12-17 2024-07-25 Genentech, Inc. Antikūnai prieš cd3 ir jų naudojimo būdai
PL3488862T3 (pl) 2014-03-25 2022-08-29 Boehringer Ingelheim Animal Health USA Inc. Kompozycje immunologiczne zawierające atenuowany Histophilus somni
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
MX2017006571A (es) * 2014-11-20 2017-09-29 Hoffmann La Roche Moleculas de union a antigeno biespecificas activadoras de celulas t.
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3095792A1 (en) 2015-05-19 2016-11-23 Klinikum rechts der Isar der Technischen Universität München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10130693B2 (en) 2015-08-28 2018-11-20 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
WO2017060201A1 (en) 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
AU2016342041B2 (en) 2015-10-23 2021-12-02 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
WO2017181001A1 (en) 2016-04-15 2017-10-19 Trustees Of Dartmouth College High affinity b7-h6 antibodies and antibody fragments
US11732020B2 (en) 2016-06-17 2023-08-22 Medigene Immunotherapies Gmbh T cell receptors and uses thereof
EP3475938B1 (en) 2016-06-27 2020-12-23 The Procter and Gamble Company Apparatus and method for assessing tooth-sensitivity treatment by oral-care product
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP7012364B2 (ja) 2016-08-05 2022-02-14 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
CN106831996B (zh) * 2017-03-31 2020-05-19 北京智仁美博生物科技有限公司 具有cd3e和/或her2靶向功能的双特异性抗体及其用途
KR20200020703A (ko) 2017-06-01 2020-02-26 우니베르지테트 스튜트가르트 이종이량체화 Ig 도메인
AU2018298884A1 (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
CN109468278A (zh) 2017-09-08 2019-03-15 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
US20210041435A1 (en) 2018-01-31 2021-02-11 Tohoku University Method for regulating antigen-specific mhc expression
EP3794035A1 (en) 2018-05-14 2021-03-24 Immunocore Limited Bifunctional binding polypeptides
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
AU2020315325A1 (en) 2019-07-15 2022-02-17 Neogene Therapeutics B.V. Method to isolate TCR genes
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4025598A1 (en) 2019-09-06 2022-07-13 Eli Lilly and Company Proteins comprising t-cell receptor constant domains
US20220396635A1 (en) 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
BR112022004789A2 (pt) 2019-09-27 2022-06-21 Agenus Inc Proteínas heterodiméricas
KR20220098379A (ko) 2019-11-15 2022-07-12 그릿스톤 바이오, 인코포레이티드 공유 네오항원을 표적으로 하는 항원-결합 단백질
EP4061827A1 (en) 2019-11-18 2022-09-28 BioNTech SE Prame tcr receptors and uses thereof
EP4077370A4 (en) 2019-12-17 2024-02-28 The Johns Hopkins University MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
EP4121079A1 (en) 2020-03-16 2023-01-25 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
WO2021188601A1 (en) 2020-03-16 2021-09-23 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
JP2023528992A (ja) 2020-06-10 2023-07-06 ザ ユニバーシティー オブ メルボルン Ｈｉｖ－１抗体
US20230272071A1 (en) 2020-07-27 2023-08-31 Michael S. Kuhns Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination
WO2022076788A1 (en) 2020-10-09 2022-04-14 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
JP2023554119A (ja) 2020-12-21 2023-12-26 ザイムワークス ビーシー インコーポレイテッド 安定化されたｔｃｒコンストラクト及び使用方法
IL305175A (en) 2021-02-19 2023-10-01 Angeles Therapeutics Inc Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Also Published As

Publication number Publication date
LT3428194T (lt) 2021-12-10
KR20200026994A (ko) 2020-03-11
US20190016803A1 (en) 2019-01-17
MA46299B1 (fr) 2021-09-30
CA3069610A1 (en) 2019-01-17
TWI762677B (zh) 2022-05-01
US11905328B2 (en) 2024-02-20
HRP20211744T1 (hr) 2022-02-04
CO2020001029A2 (es) 2020-02-18
MD3428194T2 (ro) 2022-02-28
JP2019023184A (ja) 2019-02-14
JP2020530762A (ja) 2020-10-29
PL3428194T3 (pl) 2022-01-17
SI3428194T1 (sl) 2021-12-31
US20220195044A1 (en) 2022-06-23
CY1124835T1 (el) 2022-11-25
WO2019012141A1 (en) 2019-01-17
TW201908340A (zh) 2019-03-01
US20190016802A1 (en) 2019-01-17
ES2871146T3 (es) 2021-10-28
WO2019012138A1 (en) 2019-01-17
DK3652215T3 (da) 2021-05-25
PL3652215T3 (pl) 2021-08-02
RS62544B1 (sr) 2021-12-31
KR20200026995A (ko) 2020-03-11
EP3428194A1 (en) 2019-01-16
TWI817302B (zh) 2023-10-01
MA46299A (fr) 2019-07-31
HUE054568T2 (hu) 2021-09-28
US20230348598A1 (en) 2023-11-02
DK3428194T3 (da) 2021-11-15
EP3652215A1 (en) 2020-05-20
BR112020000762A2 (pt) 2020-07-21
EP3652215B1 (en) 2021-02-17
BR112020000769A2 (pt) 2020-07-21
LT3652215T (lt) 2021-05-25
PT3428194T (pt) 2021-11-18
JP6784724B2 (ja) 2020-11-11
MX2020011744A (es) 2021-01-08
AU2018298884A1 (en) 2020-02-27
TW202246330A (zh) 2022-12-01
EP3428194B1 (en) 2021-08-18
JP2023103451A (ja) 2023-07-26
CN110914308A (zh) 2020-03-24
RS61817B1 (sr) 2021-06-30
JP2024023385A (ja) 2024-02-21
US20220185888A1 (en) 2022-06-16
SI3652215T1 (sl) 2021-08-31
PE20200615A1 (es) 2020-03-11
PT3652215T (pt) 2021-05-18
CO2020001491A2 (es) 2020-02-28
CA3069842A1 (en) 2019-01-17
CY1124091T1 (el) 2022-05-27
ES2898210T3 (es) 2022-03-04
US20190016804A1 (en) 2019-01-17
EP3985029A1 (en) 2022-04-20
CR20200013A (es) 2020-03-11
MD3652215T2 (ro) 2021-06-30
CN110914307A (zh) 2020-03-24
SG11202000027WA (en) 2020-02-27
SG11202000025SA (en) 2020-02-27
US20190016801A1 (en) 2019-01-17
CR20200014A (es) 2020-06-11
ZA202000842B (en) 2022-06-29
HUE057110T2 (hu) 2022-04-28
AU2018298881A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
PE20200614A1 (es) Molecula de polipeptido con especificidad dual mejorada
CU20180121A7 (es) Receptores de antígenos quiméricos y células t
JOP20210076A1 (ar) تركيبات أجسام مضادة ثنائية الاختصاص لربط خلايا تائية
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
CL2021000479A1 (es) Métodos de preparación de células que expresan receptores de antígenos quiméricos
AR104718A1 (es) Receptores de antígenos quiméricos específicos de anti-gd3 para inmunoterapias contra el cáncer
GT201300233A (es) Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2
CR20140585A (es) Proteinas de union a antigeno st2
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
CY1121743T1 (el) Μονοκλωνικα αντισωματα προς χρηση στη διαγνωση και θεραπεια απο καρκινους και αυτοανοση νοσο
CL2019002686A1 (es) Formatos mejorados de receptor de unión a antígeno.
AR115052A1 (es) Anticuerpos multiespecíficos y utilización de los mismos
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
EA201891459A1 (ru) Новое поколение антигенспецифических tcr
AR112228A1 (es) Molécula de polipéptido con especificidad dual mejorada
WO2019005640A3 (en) MULTISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING SAME
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CO2021014072A2 (es) Anticuerpos biespecíficos
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
MX2017007209A (es) Prueba y metodo para determinar anticuerpos de produccion de citotoxicidad dependiente del complemento (cdc).
CL2020000097A1 (es) Molécula de polipéptido con especificidad dual mejorada.
EA202090250A1 (ru) Усовершенствованная молекула полипептида с двойной специфичностью
AR117578A1 (es) Anticuerpos específicos para cd3 y sus usos
CO2023013550A2 (es) Polipéptido de unión a gucy2c y usos del mismo